Target intelligence / Profile preview

Canine adenovirus type 2 capsid protein (CAV-2 capsid antigens)

Target
CAV-2 capsid antigens
Molecular classification
Viral protein, Other
01

Overview

Canine adenovirus type 2 (CAV-2) capsid antigens are the structural proteins—primarily hexon, penton base, and fiber—that constitute the outer shell of the virus. These proteins play a fundamental role in the viral infection cycle; the fiber protein mediates high-affinity binding to the host's coxsackievirus and adenovirus receptor (CAR), while the penton base facilitates internalization via integrin interactions. In clinical practice, these antigens are the primary targets for veterinary vaccines, where they serve as immunogens to elicit neutralizing antibodies that prevent respiratory infections known as infectious tracheobronchitis or "kennel cough". Unlike CAV-1, which causes systemic hepatitis, CAV-2 is localized to the respiratory tract, making its capsid antigens safer for use in modified-live vaccines to provide cross-protection against both viral strains without the risk of "blue eye" (corneal edema). Furthermore, the unique tropism of the CAV-2 capsid for neuronal cells has led to its development as a potent vector for gene therapy in the central nervous system. Therapeutic intervention typically focuses on the induction of a robust immune response through vaccination, where the capsid antigens act as the target for neutralizing antibodies that prevent viral infection.

Other names
CAV-2 structural proteinsCanine adenovirus 2 hexonCanine adenovirus 2 fiberCanine adenovirus 2 penton
02

Mechanism of action

Induction of active immunity through the production of neutralizing antibodies that target viral capsid proteins to prevent host cell attachment and entry.

03

Biological functions

Immune responseOther
04

Disease associations

Infection
05

Safety considerations

Injection site reactionsAnaphylaxisLethargyFever
06

Interacting drugs

Canine adenovirus type 2 vaccine (modified-live virus)

3 more in the full profile.

07

Biomarkers

Anti-CAV-2 neutralizing antibody titerSerum neutralization test results

Beyond the preview

Go deeper on Canine adenovirus type 2 capsid protein (CAV-2 capsid antigens).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Canine adenovirus type 2 capsid protein (CAV-2 capsid antigens).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call